CL2022001458A1 - Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc) - Google Patents

Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)

Info

Publication number
CL2022001458A1
CL2022001458A1 CL2022001458A CL2022001458A CL2022001458A1 CL 2022001458 A1 CL2022001458 A1 CL 2022001458A1 CL 2022001458 A CL2022001458 A CL 2022001458A CL 2022001458 A CL2022001458 A CL 2022001458A CL 2022001458 A1 CL2022001458 A1 CL 2022001458A1
Authority
CL
Chile
Prior art keywords
aavc
cancer
treatment
cancer treatment
effective
Prior art date
Application number
CL2022001458A
Other languages
English (en)
Inventor
Ohsumi Keisuke
Yoshida Taku
Kanki Masayuki
Fujii Shinichiro
Shimizu Kanako
Original Assignee
Astellas Pharma Inc
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Riken filed Critical Astellas Pharma Inc
Publication of CL2022001458A1 publication Critical patent/CL2022001458A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Abstract

Se proporciona un método efectivo y seguro para tratar o prevenir un cáncer utilizando aAVC. La presente invención encuentra escala apropiadas de la dosis de α-GalCer cargado en la superficie de la célula aAVC, así como la cantidad de α-GalCer cargado en la superficie de la célula aAVC, en una composición farmacéutica que contiene aAVC, las cuales se prefieren en términos de garantizar la efectividad y seguridad en el tratamiento y prevención de un cáncer utilizando aAVC; y proporciona un método efectivo y seguro para el tratamiento o prevención de un cáncer utilizando aAVC para el tratamiento efectivo y seguro de un cáncer; y una composición farmacéutica que comprende a la misma, etc.
CL2022001458A 2019-12-02 2022-06-02 Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc) CL2022001458A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019217712 2019-12-02

Publications (1)

Publication Number Publication Date
CL2022001458A1 true CL2022001458A1 (es) 2023-02-24

Family

ID=76222356

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001458A CL2022001458A1 (es) 2019-12-02 2022-06-02 Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)

Country Status (20)

Country Link
US (2) US11617790B2 (es)
EP (1) EP4070810A4 (es)
JP (2) JP6912765B1 (es)
KR (1) KR20220119029A (es)
CN (1) CN114929272A (es)
AR (1) AR122341A1 (es)
AU (1) AU2020398783A1 (es)
BR (1) BR112022010750A2 (es)
CA (1) CA3162121A1 (es)
CL (1) CL2022001458A1 (es)
CO (1) CO2022008737A2 (es)
CR (1) CR20220319A (es)
DO (1) DOP2022000109A (es)
EC (1) ECSP22049665A (es)
IL (1) IL293483A (es)
JO (1) JOP20220122A1 (es)
MX (1) MX2022006712A (es)
PE (1) PE20221421A1 (es)
TW (1) TW202134265A (es)
WO (1) WO2021112056A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
EP1990410B1 (en) * 2006-02-22 2020-01-08 Riken IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
EP1990410B1 (en) 2006-02-22 2020-01-08 Riken IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
US20110280895A1 (en) 2008-11-28 2011-11-17 Riken IMMUNOTHERAPEUTIC METHOD USING ALLO-CELLS WHICH CO-EXPRESS CD1d AND TARGET ANTIGEN
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
KR20130018778A (ko) 2010-03-25 2013-02-25 쓰리엠 이노베이티브 프로퍼티즈 컴파니 복합 층
EP2738253A4 (en) 2011-07-29 2015-04-22 Riken CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product

Also Published As

Publication number Publication date
US20230381305A1 (en) 2023-11-30
AU2020398783A1 (en) 2022-06-09
US11617790B2 (en) 2023-04-04
JPWO2021112056A1 (ja) 2021-12-02
JP2021155443A (ja) 2021-10-07
JOP20220122A1 (ar) 2023-01-30
PE20221421A1 (es) 2022-09-20
CO2022008737A2 (es) 2022-08-09
IL293483A (en) 2022-08-01
TW202134265A (zh) 2021-09-16
EP4070810A4 (en) 2024-04-17
KR20220119029A (ko) 2022-08-26
BR112022010750A2 (pt) 2022-08-16
MX2022006712A (es) 2022-09-12
EP4070810A1 (en) 2022-10-12
WO2021112056A1 (ja) 2021-06-10
DOP2022000109A (es) 2022-10-16
CN114929272A (zh) 2022-08-19
US20220016239A1 (en) 2022-01-20
JP6912765B1 (ja) 2021-08-04
CA3162121A1 (en) 2021-06-10
AR122341A1 (es) 2022-09-07
CR20220319A (es) 2022-11-03
ECSP22049665A (es) 2022-08-31

Similar Documents

Publication Publication Date Title
CL2022001458A1 (es) Método para el tratamiento de cáncer utilizando célula ad-yuvante artificial (aavc)
CL2023000847A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
AR105712A1 (es) Composiciones de insulina de rápida acción
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CL2022000194A1 (es) Uso para tratar la enfermedad de hemorragia alveolar difusa asociada con trasplante de células madre hematopoyéticas (divisional de la solicitud no. 202000384)
CL2019001415A1 (es) Composición para promover la diferenciación de y para proteger las células madre neuronales y método para inducir la regeneración neural utilizando la misma.
CL2023002383A1 (es) Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
CO2017006983A2 (es) Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
CL2018002734A1 (es) Métodos de tratamiento con vitamina d
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
NI202000052A (es) Terapia de combinación para tratar o prevenir el cáncer
CL2021003170A1 (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CL2021001096A1 (es) Métodos para tratar el síndrome mielodisplásico. (divisional de la solicitud no. 202000196)
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CL2021001638A1 (es) Tratamiento del cáncer con docetaxel controlando los niveles plasmáticos máximos
UY38948A (es) Régimen de dosificación para agentes anti-dll3
CL2019001924A1 (es) Composición fungicida efectiva contra alternaria en cítricos. (divisional solicitud 201701815)
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
BR112018071023A2 (pt) combinações para o tratamento de neoplasmas utilizando o direcionamento de células inativas e inibidores da mitose